Biocomposites has taken a minority-share interest in Renovos Biologics, a biologics company born out of research into the properties of nanoclay at the University of Southampton, UK.
Renovos’ lead product RENOVITE is a synthetic, biodegradable nanoclay carrier that can be used to place a wide range of pharmaceutical drugs and biologics at the site of treatment. It can be injected through a 23-gauge cannula in support of minimally invasive procedures and sets into a stiff gel upon contact with physiological fluids, such as blood serum. As a cell-responsive carrier, it requires a lower dose of therapeutic drug to accelerate healing.
The investment from Biocomposites will allow Renovos to access Biocomposites’ expertise in the development of drug carriers to progress RENOVITE to premarket approval as a carrier for use in spine, trauma and orthopedics. It will further provide Renovos access to Biocomposites’ global distribution network.
Michael Harris, Chief Executive Officer of Biocomposites, said, “The potential for RENOVITE as a next generation drug carrier that can enhance the activity of therapeutic drugs at lower doses, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting. Following on from our recent acquisition of Artoss in June this year, and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”
Biocomposites has taken a minority-share interest in Renovos Biologics, a biologics company born out of research into the properties of nanoclay at the University of Southampton, UK.
Biocomposites has taken a minority-share interest in Renovos Biologics, a biologics company born out of research into the properties of nanoclay at the University of Southampton, UK.
Renovos’ lead product RENOVITE is a synthetic, biodegradable nanoclay carrier that can be used to place a wide range of pharmaceutical drugs and biologics at the site of treatment. It can be injected through a 23-gauge cannula in support of minimally invasive procedures and sets into a stiff gel upon contact with physiological fluids, such as blood serum. As a cell-responsive carrier, it requires a lower dose of therapeutic drug to accelerate healing.
The investment from Biocomposites will allow Renovos to access Biocomposites’ expertise in the development of drug carriers to progress RENOVITE to premarket approval as a carrier for use in spine, trauma and orthopedics. It will further provide Renovos access to Biocomposites’ global distribution network.
Michael Harris, Chief Executive Officer of Biocomposites, said, “The potential for RENOVITE as a next generation drug carrier that can enhance the activity of therapeutic drugs at lower doses, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting. Following on from our recent acquisition of Artoss in June this year, and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”
Copy to clipboard 
